Evan Loh - 08 Aug 2023 Form 4 Insider Report for Paratek Pharmaceuticals, Inc.

Role
CEO, Director
Signature
/s/ William M. Haskel, Attorney-in-Fact for Evan Loh
Issuer symbol
N/A
Transactions as of
08 Aug 2023
Net transactions value
-$107,727
Form type
4
Filing time
10 Aug 2023, 20:26:53 UTC
Previous filing
03 Mar 2023
Next filing
21 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Award $0 +168,750 +14% $0.000000 1,376,948 08 Aug 2023 Direct F1
transaction PRTK Common Stock Sale $107,727 -48,967 -3.6% $2.20 1,327,981 09 Aug 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance-based restricted stock units ("PRSUs") granted on March 30, 2021 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2023.
F2 Sale of shares to cover personal income tax obligations upon vesting of PRSUs.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.19 to $2.21. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.